PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations

References

• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non Small-Cell Lung Cancer. N Engl J Med 2015; 373(2):123-3; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8):908-18; PMID:26115796; http://dx.doi.org/10.1016/S1470-2045(15)00083-2
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015. 372(21):2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(17):1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, Chow LQM, Vokes EE, Felip E, Holgado E et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advancednon-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33 (suppl):LBA109.
   Google Scholar
• Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4):375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• FDA News Release 2015-09-10, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm
   Google Scholar
• FDA News Release 2015-04-10, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
   Google Scholar
• Schultheis AM, Scheel AH, Ozretić L, George J, Thomas RK, Hagemann T, Zander T, Wolf J, Buettner R. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015; 51(3):421-6; PMID:25582496; http://dx.doi.org/10.1016/j.ejca.2014.12.006
   PubMed Web of Science ®Google Scholar
• Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015; 28(9):1154-66; PMID:26183759; http://dx.doi.org/10.1038/modpathol.2015.63
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(1):23-3; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015; 14(4):847-56; PMID:25695955; http://dx.doi.org/10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, IASLC Pathology Committee. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol 2015; 10(7):985-9; PMID:26134220; http://dx.doi.org/10.1097/JTO.0000000000000526
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8(8):793-800; PMID:12091876; http://dx.doi.org/10.1038/nm730
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Seidel D, Zander T, Heukamp LC, Peifer M, Bos M, Fernandez-Cuesta L, Leenders F, Lu X, Ansen S, Gardizi M et al. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5(209):209ra153; PMID:24174329; http://dx.doi.org/10.1126/scitranslmed.3006802
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Kowanetz M, Koeppen H, Wistuba II, Kockx M, Kadel EE, Rizvi NA, Spira AI, Hirsch FR, Boyd Z et al. Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. J Clin Oncol 2015; 33 (suppl; abstr 3015); PMID:25897158; http://dx.doi.org/10.1200/JCO.2014.58.3708
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11(2):155-68; PMID:9504686
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457(3):299-307; PMID:20665045; http://dx.doi.org/10.1007/s00428-010-0952-2
   PubMed Web of Science ®Google Scholar
• Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Cali∫ A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One 2015; 10(6); PMID:26086854; http://dx.doi.org/10.1371/journal.pone.0130142
   PubMed Web of Science ®Google Scholar
• Yearly J, Gibson C, Yu N, Moon C, Murphy E, McClanahan T. PD-l2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Eur J Cancer 2015; 51(S3):18LBA.
   Google Scholar
• Taube JM. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology 2014 Dec 21; 3(11):e963413; PMID:25914862; http://dx.doi.org/10.4161/21624011.2014.963413
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MH, Goldinger SM et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 2015; 350(6257):207-11; PMID:26359337; http://dx.doi.org/10.1126/science.aad0095
   PubMed Web of Science ®Google Scholar
• Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94:107-16; PMID:24217091; http://dx.doi.org/10.1038/labinvest.2013.130
   PubMed Web of Science ®Google Scholar
• Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, Aubry MC. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013; 14:157-63; PMID:22868219; http://dx.doi.org/10.1016/j.cllc.2012.05.006
   PubMed Web of Science ®Google Scholar
• Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015; 89(2):181-8; PMID:26024796; http://dx.doi.org/10.1016/j.lungcan.2015.05.007
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528):563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10:5094-100; PMID:15297412; http://dx.doi.org/10.1158/1078-0432.CCR-04-0428
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Miyata M, Ohba T, Ando T, Hatsushika K, Suenaga F, Shimokawa N, Ohnuma Y, Katoh R, Ogawa H et al. Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T(H)2-type immune responses and airway inflammation. J Allergy Clin Immunol 2008; 122(6):1208-14; PMID:18926564; http://dx.doi.org/10.1016/j.jaci.2008.09.022
   PubMed Web of Science ®Google Scholar
• Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 2005; 175(4):2684-91; PMID:16081845; http://dx.doi.org/10.4049/jimmunol.175.4.2684
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116(17):3268-77; PMID:20628145; http://dx.doi.org/10.1182/blood-2010-05-282780
   PubMed Web of Science ®Google Scholar
• Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative 635 breast cancer. Oncotarget 2015; 6(28):26483-93; PMID:26317899; http://dx.doi.org/10.18632/oncotarget.4494
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L. Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology 2015. 4(6):e1008853; PMID:26155425; http://dx.doi.org/10.1080/2162402X.2015.1008853
   PubMedGoogle Scholar
• Travis WD, Brambilla E, Müller-Hermelink H-K, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Geneva: World Health Organization, 2004.
   Google Scholar
• Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011; 8(5):381-5; PMID:21926387; http://dx.doi.org/10.1513/pats.201107-042ST
   PubMedGoogle Scholar
• Remotti H. Tissue microarrays: construction and use. Methods Mol Biol 2013; 980:13-28; PMID:23359147; http://dx.doi.org/10.1007/978-1-62703-287-22
   PubMedGoogle Scholar